[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Misr University for Science and Technology\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":210},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,71,98,124,158,186],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100637067","riss-versus-lower-thoracic-esp-block-for-analgesia-after-laparoscopic-abdominal-surgery-a-randomized-trial-100637067",false,"NCT07593300","RISS Versus Lower Thoracic ESP Block for Analgesia After Laparoscopic Abdominal Surgery: A Randomized Trial","Analgesic Efficacy of Ultrasound-Guided Rhomboid Intercostal and Subserratus (RISS) Block Versus Lower Thoracic Erector Spinae Plane Block (ESPB) After Abdominal Laparoscopic Surgery","Inclusion Criteria:\n\n* Patients scheduled for laparoscopic abdominal surgery (e.g., cholecystectomy, colectomy, sleeve gastrectomy, hernia repair, appendectomy).\n* Age from 18 - 60 years old.\n* Both sexes.\n* American Society of Anesthesiology (ASA) classification I, II. (i.e., ASA I: a normal healthy patient; ASA II: patients with mild controlled systemic disease.\n\nExclusion Criteria:\n\n* Patients who refuse the research consent.\n* Allergy to local anesthetic drugs.\n* Cardiac arrhythmia.\n* Bleeding tendency (including pre-existing blood disease and patients on full anticoagulant therapy).\n* Morbid obese patients (BMI\\>35 kg\u002Fm2)\n* Vascular compromise of lower extremity (e.g., Burger disease, Raynaud's disease).\n* Connective tissue disease (e.g., Scleroderma).\n* Suspected malignancy or intra-abdominal infection.",true,"ALL","18 Years","60 Years",{"count":21,"type":22},70,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to investigate the analgesic efficacy of ultrasound-guided Romboid Intercostal and Subserratus (RISS) block versus lower thoracic Erector Spinae Plane (ESP) block after laparoscopic abdominal surgery. The main questions it aims to answer are:\n\nDoes ultrasound-guided Romboid Intercostal and Subserratus (RISS) block is effective as the lower thoracic Erector Spinae Plane (ESP) block for intra and postoperative analgesia after laparoscopic abdominal surgery for the first 24 hours? What complications do participants have when doing these interventions?\n\nResearchers will compare the analgesic efficacy of ultrasound-guided Romboid Intercostal and Subserratus (RISS) block with the lower thoracic Erector Spinae Plane (ESP) block after laparoscopic abdominal surgery.\n\nParticipants will:\n\nStart general anesthesia and be given either block according to the randomization chart.\n\nThe blood pressure and heart rate will be measured at intervals to determine if the participants need extra intraoperative analgesics.\n\nNumerical Rating Scale (NRS) will be used postoperatively to test pain severity.\n\nRescue morphine analgesia will be measured and compared in both groups.\n\nAny complications will be reported.\n\nPatient and surgeon satisfaction will be measured.",[28],"Pain After Surgery",[30,31,32],"Erector Spine Plane Block","Laparoscopic surgery","Rhomboid Intercostal block","NOT_YET_RECRUITING","2026-05-13",{"date":36,"type":37},"2026-05-18","ACTUAL",{"date":39,"type":22},"2026-05-20",{"date":41,"type":22},"2026-12-31",{"name":43,"class":44},"Misr University for Science and Technology","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":45},"100629247","phase-2-comparative-study-for-facial-scar-remodeling-using-fractional-carbon-dioxide-laser-combined-with-pdrn-versus-fractional-co-laser-100629247","NCT07472192","Comparative Study for Facial Scar Remodeling Using Fractional Carbon Dioxide Laser Combined With PDRN Versus Fractional CO₂ Laser","Comparative Study for Facial Scar Remodeling Using Fractional Carbon Dioxide Laser Combined With Polydeoxyribonucleotide (PDRN) Versus Fractional CO₂ Laser: A Randomized Controlled Clinical Study","PDRN CO2 LASER","Inclusion Criteria:\n\n* Age Limitations: Participants must be between 18 and 50 years of age.\n* Recently cut wounds or surgical scars from about (1-6 months).\n* Consent to Participate: Willingness to provide informed consent and engage in all aspects of the study.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding at the time of study.\n* Known allergy to PDRN.\n* Medication use that could affect wound healing or inflammation, such as:\n\n  * Isotretinoin.\n  * Anticancer drugs.\n  * High-dose corticosteroids.\n  * Anticoagulants.\n* Uncontrolled medical diseases (e.g., unstable diabetes, cardiac conditions).","50 Years",{"count":56,"type":22},36,[58],"PHASE2","Facial scars are frequently deemed unpleasant and can profoundly impact a patient's psychological health. This study compares the effectiveness, safety, and capacity to speed up scar healing in the maxillofacial region between fractional carbon dioxide (CO₂) laser therapy alone and polydeoxyribonucleotide (PDRN) combined with CO₂ laser therapy.",[61],"Facial Scarring","RECRUITING","2026-03-11",{"date":65,"type":37},"2026-03-16",{"date":67,"type":37},"2026-03-01",{"date":69,"type":22},"2026-07-01",{"name":43,"class":44},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100625306","phase-1-antibacterial-effect-and-post-operative-pain-following-various-techniques-of-intracanal-heating-of-naocl-100625306","NCT07420920","Antibacterial Effect and Post-operative Pain Following Various Techniques of Intracanal Heating of NaOCL","Assessment of the Antibacterial Effect and Post-operative Pain Following Various Techniques of Intracanal Heating of Sodium Hypochlorite: A Randomized Clinical Trial","Inclusion Criteria:\n\nFor patients:\n\n* adult male or female patients\n* medically free.\n\nFor selected teeth:\n\n* asymptomatic necrotic single rooted teeth\n* teeth with mature root\n* restorable teeth.\n\nExclusion Criteria:\n\nFor patients:\n\n* Patients with dental related symptoms\n* patients with chronic or systemic diseases\n* pregnant females.\n\nFor selected teeth:\n\n* multirooted teeth\n* vital teeth\n* teeth with incompletely formed roots\n* teeth with internal or external resorption\n* previously root canal treated teeth",{"count":56,"type":22},[80,58],"PHASE1","The goal of this clinical trial is to is to assess the antibacterial effect of sodium hypochlorite heated inside root canals of necrotic teeth using various activation techniques\n\nThe main question it aims to answer is:\n\nDoes the antibacterial effect vary following various standardized techniques of intracanal heating of sodium hypochlorite in endodontic treatment?",[83],"Necrotic Teeth",[85,86,87,88,89],"Necrotic teeth,","Endodontic irriggation","Irrigation activation","Intracanal heating","Sodium hypochlorite","2026-02-11",{"date":92,"type":37},"2026-02-19",{"date":94,"type":22},"2026-02-10",{"date":96,"type":22},"2026-06",{"name":43,"class":44},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":108,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":45},"100574225","effect-of-feldenkrais-method-on-balance-in-patients-with-mechanical-low-back-pain-100574225","NCT06756516","Effect of Feldenkrais Method on Balance in Patients With Mechanical Low Back Pain","Effect of Feldenkrais Method on Balance in Patients With Mechanical Low Back Pain: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Mechanical back pain.\n* Symptoms lasted for the last 6 months.\n* Not referring beyond the knee.\n* Mild to moderate pain in Numerical Pain Rating Scale and mild to moderate disability on Oswestry Disability Index\n\nExclusion Criteria:\n\n* Spine Surgeries\n* Chronic diseases\n* Accidents and Fractures","45 Years",{"count":107,"type":22},40,[25],"The goal of this clinical trial is to learn if Feldenkrais method affects balance in patients with mechanical low back pain. The main questions it aims to answer is:\n\ndoes Feldenkrais method affects balance in patients with mechanical low back pain.\n\nParticipants will:\n\nBe assessed for inclusion using slump and straight leg raise tests. Visit the clinic twice every week for sessions. Assessed pre and post treatment using Biodex Balance.",[111],"Mechanical Low Back Pain",[113,114,115],"Feldenkrais method","mechanical low back pain","balance","2024-12-31",{"date":118,"type":37},"2025-01-03",{"date":120,"type":37},"2024-11-27",{"date":122,"type":22},"2025-05-28",{"name":43,"class":44},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":132,"maxAge":54,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":137,"conditions":138,"keywords":141,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":45},"100568073","phase-2-comparison-between-botox-and-magnesium-sulfate-effect-in-treatment-of-myofascial-pain-trigger-points-within-the-masseter-muscle-100568073","NCT06676475","Comparison Between Botox and Magnesium Sulfate Effect in Treatment of Myofascial Pain Trigger Points Within the Masseter Muscle","Comparison of the Effectiveness of Botulinum Toxin and Magnesium Sulfate Injections in the Treatment of Myofascial Trigger Points in the Masseter Muscle Randomized Controlled Clinical Trial","MPS MTrPs BTA","Inclusion Criteria:\n\n* Patients diagnosed with orofacial pain and trigger points in the masseter muscle unilaterally or bilaterally for at least period 6 months other criteria\n* Definite diagnosis of myofascial pain based on the DC\u002FTMD criteria with a referral\n* Presence of one or more unilateral or bilateral trigger points in the masseter muscle\n* No history of any invasive procedures of the related masseter muscle (Taşkesen, Cezairli, 2023.)\n\nExclusion Criteria:\n\n* Any painful conditions (other than myofascial trigger points) affecting the orofacial region\n* Any systemic diseases that could affect masticatory function (e.g., rheumatoid arthritis and epilepsy\n* Pregnancy and lactation. (Refahee, Mahrous, Shabaan,2022)","16 Years",{"count":134,"type":22},60,[58,136],"PHASE3","The goal of this randomized clinical trial is to compare the effectiveness of Botulinum toxin type A, magnesium sulfate and saline injections in treatment of the masseter muscle trigger points, in patients between 16 - 50 years old with myofascial pain with masseter muscle trigger points. The main questions it aims to answer are:\n\n* which treatment has longer effect of pain release with the least possible side effects and recurrence rate?\n* Which treatment has greater impact on improving patient's quality of life? Researchers will compare Botulinum toxin type A, magnesium sulfate to a placebo saline injections in treatment of the masseter muscle trigger points Participants will attend to the clinic 4 times\n* 1st visit will include taking preoperative records and treatment injection\n* 2nd visit will be follow up and taking records after 1 month\n* 3rd visit will be follow up and taking records after 3 months\n* 4th visit will be follow up and taking records after 6 months",[139,140],"Myofacial Pain","Trigger Points, Myofascial",[142,143,144,145,146,147,148,149],"myofascial pain","masseter trigger point","MPS","MTrPs","MgSO4 in myofascial trigger points","BTA in myofascial trigger points","Botox in masseter trigger points","magnesium sulfate in masseter trigger points","2024-11-08",{"date":152,"type":37},"2024-11-12",{"date":154,"type":22},"2024-12-01",{"date":156,"type":22},"2025-08",{"name":43,"class":44},{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":4},"100561811","phase-2-lidocaine-versus-magnesium-sulphate-in-management-of-myofascial-pain-dysfunction-syndrome-100561811","NCT06595017","Lidocaine Versus Magnesium Sulphate in Management of Myofascial Pain Dysfunction Syndrome","Evaluation of the Effect of Magnesium Sulfate Injection in Comparison to Lidocaine for Management of Myofascial Pain Dysfunction Syndrome: a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Age Limitations: Participants must be between 18 and 55 years old.\n* Chronic Pain Diagnosis: Individuals must have a diagnosis of chronic myofascial pain dysfunction syndrome (MPDS) affecting the face muscles, neck, shoulder, or upper back for a duration exceeding three months.\n* Trigger Point Recognition: Patients must show awareness of their pain when pressure is applied to identified myofascial trigger points, in accordance with established diagnostic guidelines.\n* Consent to Participate: Willingness to provide informed consent and engage in all aspects of the study.\n\nExclusion Criteria:\n\n* Previous Treatments: A history of receiving dry needling or pulsed radiofrequency therapy, or currently participating in other pain management treatments.\n* Recent Injury or Surgery: Any recent trauma, surgical procedures, or infections in the affected area within the past six months.\n* Medication Interference: Current or recent use of moderate to strong analgesics (e.g., tramadol, morphine) that could influence pain assessment.\n* Severe Health Conditions: Individuals with significant systemic illnesses (e.g., severe liver or kidney disease), blood clotting disorders, rheumatoid arthritis or epilepsy.\n* Mental Health: Presence of current psychiatric disorders, cognitive impairments, or inability to comply with the study protocol.","55 Years",{"count":167,"type":22},75,[58],"The goal of this clinical trial is to investigate the effectiveness of Magnesium Sulphate in the management of myofascial pain dysfunction syndrome in comparison to Lidocaine and Saline.\n\nA total of 75 patients suffering from myofascial pain dysfunction syndrome will be assigned into one of three groups, each with 25 patients.\n\nGroup A: (Saline) includes patients enrolled for Saline injection into the trigger points. Group B: (Magnesium Sulphate) includes patients enrolled for Magnesium Sulphate injection into the trigger points. Group C: (Lidocaine) includes patients who will be enrolled for Lidocaine injection into the trigger points The primary outcome that will be investigated is (pain with a visual analogue score), and secondary outcomes will be (maximum mouth opening between edges of upper and lower incisors with millimeters, electrical activity with Electromyography, and quality of life assessed using the Oral Health Impact Profile questionnaire) The outcomes will be assessed pre-injection, 1month after injection, 3months after injection, and 6 months after injection",[171],"Myofascial Pain Dysfunction Syndrome",[173,174,175,176,177],"Myofascial pain dysfunction syndrome","Magnesium Sulphate","Lidocaine","Pain","Electromyography","2024-09-17",{"date":180,"type":37},"2024-09-19",{"date":182,"type":22},"2024-10-01",{"date":184,"type":22},"2025-11-30",{"name":43,"class":44},{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":193,"targetDuration":4,"studyType":23,"phases":195,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":207,"leadSponsor":209,"locationsCount":4},"100560534","effect-of-internal-and-external-micro-needling-in-treatment-of-stage-iii-periodontitis-100560534","NCT06578403","Effect of Internal and External Micro-needling in Treatment of Stage III Periodontitis","Minimally Invasive Non-surgical Therapy Augmented With Internal Versus External Micro-needling in Treatment of Stage Iii Periodontitis: a Randomized Controlled Clinical Trial and Biochemical Trial","Inclusion Criteria:\n\n* Male or Female systematic health\n* age ≥ 18 years\n* Provide informed consent and willingness to cooperate with the study protocol.\n* Periodontitis stage III patients:\n* Probing depth≥6 mm\n* CAL ≥5 mm.\n* Radiographic bone loss (Extending to middle and beyond)\n* Tooth loss ≥4 teeth.\n* Each patient contributed a maximum of two sides.\n\nExclusion Criteria:\n\n* smoker\n* History of antibiotic in previous three months.\n* Pregnant or lactating.\n* Treatment with any systemic drug that influences the healing of hard and soft tissues.\n* Patients who received periodontal treatment in the last 6 months",{"count":194,"type":22},66,[25],"Periodontitis is a dysbiotic disease characterized by the destruction of the periodontium (alveolar bone, cementum, periodontal ligament, gingiva) and considered the main cause of tooth loss which is linked to a change in the microbial community from primarily beneficial bacteria, known as 'symbionts', to an imbalance with a high presence of harmful bacteria 'dysbiosis', also known as 'pathobionts'.\n\nIdeally, periodontal therapy should eliminate inflammation, arrest the advancement of periodontal disease, enhance appearance, and create an environment conducive to health maintenance.Microneedling (MN) is known as \"percutaneous collagen induction therapy.\" Micro injuries created by MN result in minimal superficial bleedings and create a wound-healing The body responds to micro-needling as if it's experiencing tissue trauma, leading to the release of various growth factors such as platelet-derived growth factors, transforming growth factors, connective tissue growth factors, and fibroblast growth factors. These growth factors induce the production of collagen to preserve skin integrity. After an injury, growth factors are released, promoting the proliferation of new cells. From day 5 to week 8, fibroblasts produce collagen and elastin fibers, thickening the tissue in a process known as neocollagenesis. Additionally, fibroblasts trigger neoangiogenesis by stimulating the proliferation of endothelial cells in the vessels. According to a randomized clinical trial comparing micro-needling and acellular dermal matrix, significant improvements were observed in various parameters(GT, RW, RD, CAL, PD, Rec- Red, and percentage of root coverage, with reduced PI and BOP at 3 and 6 months this study aim to The effect of minimally invasive non-surgical augmented with micro-needling, both externally and internally, for the management of stage III periodontitis",[198],"Periodontal Diseases",[200,201,202],"microneedling","periodontitis","Minimally invasive non-surgical therapy","2024-08-27",{"date":205,"type":37},"2024-08-29",{"date":154,"type":22},{"date":208,"type":22},"2025-09-30",{"name":43,"class":44},""]